Research status of mesenchymal stem cell therapy for COVID-19

Q4 Medicine

武汉大学学报(医学版) Pub Date : 2021-01-01 DOI:10.14188/j.1671-8852.2020.0367

M. Wang, D. Yang, H. Cai

{"title":"Research status of mesenchymal stem cell therapy for COVID-19","authors":"M. Wang, D. Yang, H. Cai","doi":"10.14188/j.1671-8852.2020.0367","DOIUrl":null,"url":null,"abstract":"The COVID-19 pandemic caused by SARS-CoV-2 is rapidly and continuously spreading globally, posing a great threat to human life and health. It is urgent to find a safe and effective treatment. Studies have found that mesenchymal stem cells (MSCs) have powerful immunoregulatory and anti-inflammatory functions. They can mitigate and repair lung injury caused by the excessive immune response to the virus and reduce the risk of cytokine storm syndrome (CSS) and acute respiratory distress syndrome (ARDS), by regulating the function of immune cells, reducing the secretion of inflammatory factors, upregulating the anti-inflammatory factors and secreting a variety of cell growth factors. In addition, MSCs are also characterized by abundant sources, easy access, low immunogenicity, no ethical controversy, the ability to target chemotaxis in damaged tissues, and virus resistance. Therefore, it is considered an effective way to treat COVID-19. In this article, we evaluated the safety and efficacy of MSCs in the treatment of COVID-19 and its possible mechanism. © 2021, Editorial Board of Medical Journal of Wuhan University. All right reserved.","PeriodicalId":35402,"journal":{"name":"武汉大学学报(医学版)","volume":"42 1","pages":"584-588"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"武汉大学学报(医学版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14188/j.1671-8852.2020.0367","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 is rapidly and continuously spreading globally, posing a great threat to human life and health. It is urgent to find a safe and effective treatment. Studies have found that mesenchymal stem cells (MSCs) have powerful immunoregulatory and anti-inflammatory functions. They can mitigate and repair lung injury caused by the excessive immune response to the virus and reduce the risk of cytokine storm syndrome (CSS) and acute respiratory distress syndrome (ARDS), by regulating the function of immune cells, reducing the secretion of inflammatory factors, upregulating the anti-inflammatory factors and secreting a variety of cell growth factors. In addition, MSCs are also characterized by abundant sources, easy access, low immunogenicity, no ethical controversy, the ability to target chemotaxis in damaged tissues, and virus resistance. Therefore, it is considered an effective way to treat COVID-19. In this article, we evaluated the safety and efficacy of MSCs in the treatment of COVID-19 and its possible mechanism. © 2021, Editorial Board of Medical Journal of Wuhan University. All right reserved.

查看原文本刊更多论文

间充质干细胞治疗COVID-19的研究现状

由SARS-CoV-2引起的新冠肺炎大流行正在全球范围内迅速持续蔓延，对人类生命健康构成巨大威胁。迫切需要找到一种安全有效的治疗方法。研究发现间充质干细胞(MSCs)具有强大的免疫调节和抗炎功能。它们可以通过调节免疫细胞功能，减少炎症因子的分泌，上调抗炎因子，分泌多种细胞生长因子，减轻和修复病毒过度免疫应答引起的肺损伤，降低细胞因子风暴综合征(CSS)和急性呼吸窘迫综合征(ARDS)的发生风险。此外，间充质干细胞还具有来源丰富、易于获取、免疫原性低、无伦理争议、在受损组织中具有靶向趋化性和病毒抗性等特点。因此，它被认为是治疗COVID-19的有效方法。在本文中，我们评估了MSCs治疗COVID-19的安全性和有效性及其可能的机制。©2021，武汉大学医学杂志编辑委员会。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊